Chemed (CHE) Cash & Equivalents (2009 - 2026)

Chemed (CHE) has reported Cash & Equivalents for 18 consecutive years, with $16.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 90.31% year-over-year to $16.9 million; the TTM figure through Mar 2026 stood at $16.9 million (down 90.31% YoY), while the FY2025 annual figure was $74.5 million, down 58.22% from the prior year.
• Cash & Equivalents came in at $16.9 million for Q1 2026 at Chemed, down from $74.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $313.3 million in Q1 2024, with the low at $7.8 million in Q3 2022.
• Average Cash & Equivalents over 5 years is $139.0 million, with a median of $159.9 million recorded in 2023.
• Across the five-year window, Cash & Equivalents sank 91.36% in 2022 and surged 2125.29% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $74.1 million in 2022, then surged by 256.09% to $264.0 million in 2023, then sank by 32.43% to $178.4 million in 2024, then slumped by 58.22% to $74.5 million in 2025, then sank by 77.38% to $16.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $16.9 million, $74.5 million, and $129.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.